About QED Therapeutics

Who we are

A subsidiary of BridgeBio, QED focuses on precision medicine for FGFR-driven cancers and diseases. We live by our name: QED, derived from the Latin “Quod Erat Demonstrandum” —Thus, It Has Been Proven.

Our business is inspired by our values.

  • Put patients first
  • Act nimbly
  • Think independently
  • Be radically transparent

What we do

With singular focus, QED is devoted to the development of our investigational candidate, infigratinib. A first-in-class, selective, tyrosine kinase inhibitor, infigratinib has promising early clinical data in patients with previously treated, FGFR-driven cholangiocarcinoma and metastatic urothelial carcinoma, as well as preclinical studies in achondroplasia. Future studies will investigate infigratinib for additional FGFR-driven tumor types and rare disorders.

FGFR=fibroblast growth factor receptor.

Our community

QED has partnered with the Cholangiocarcinoma Foundation, whose mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer). This partnership allows QED to collaborate with leading disease experts in the Cholangiocarcinoma Foundation network.

The Cholangiocarcinoma Foundation strongly encourages early molecular biomarker testing for patients with cholangiocarcinoma. When it comes to effective treatment options, mutations matter.

Cholangiocarcinoma Foundation Logo

Our Team

Michael Henderson, MD

Chief Business Officer

Michael joined BridgeBio to bring genetically targeted treatments to those patients with the highest unmet need. He is responsible for identifying and acquiring new technologies and playing a role in both the parent and subsidiary companies. Michael, who is currently serving as CBO and interim CEO for QED Therapeutics, has overseen the creation of 17 companies. He is a voting board member for 5 of BridgeBio’s subsidiary companies and cofounded PellePharm, one of BridgeBio’s portfolio companies, while in medical school. Prior to BridgeBio, Michael consulted for McKinsey & Company’s Silicon Valley Office where he served biotech clients across the US and EU. He received his BA from Harvard University and holds an MD from Stanford University. Originally from Oklahoma, he is a die-hard fan of the Oklahoma Sooners and a sworn enemy of any football team that opposes them.

Susan Moran, MD, MSCE

Chief Medical Officer

Susan has over 20 years of industry and academic experience, successfully leading clinical trials from Phase 1 to Phase 3, as well as NDA and MAA submissions for various investigational products including the successful approval of Nerlynx. Before joining QED, she was VP and Head of Clinical Development for Puma Biotechnology and previously held senior positions at Millennium and Genzyme. Susan has played roles in the development, registration, and post-marketing support of products for breast, prostate, and thyroid cancer, as well as multiple sclerosis and other disorders. She is a board-certified internist and has served on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. Susan received her BA from the University of Virginia, MD from Duke University, and MS in Clinical Epidemiology from the University of Pennsylvania School of Medicine.

Matt Outten, MBA, ALM, CPC

Chief Commercial Officer

Matt joined QED with over 20 years of pharmaceutical/biotech experience, focusing on oncology and various product launches. Before joining QED, Matt held various leadership positions at Pharmacyclics, including VP of Marketing and Market Access, VP of Commercial Operations, and Chief Commercial Officer. During his time at Pharmacyclics, Matt led the successful launch of Imbruvica for chronic lymphocytic leukemia and spearheaded launches in 5 additional disease states. Matt has also held important roles across marketing, sales, and market access at pharmaceutical and biotech companies including Millennium, Schering Plough, and GlaxoSmithKline. Matt received his BA from Hamilton College, MBA from The University of Delaware, and ALM from Harvard.

Rick Panicucci, PhD

Senior Vice President of CMC

Prior to joining BridgeBio, Rick served as VP of Pharmaceutical Development Services at WuXi STA, where he provided scientific leadership in formulation development and GMP manufacturing. From 2004 to 2015, Rick was Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis. His responsibilities included analytics, solid state chemistry, and formulation development for all small molecule therapeutics. He also helped develop novel drug delivery technologies for small molecules and large molecules including oligonucleotides. Rick has also led R&D groups at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb. He received a PhD in Chemistry from the University of Toronto and did a post-doctoral fellowship at the University of California, Santa Barbara.

Gary Li, PhD

Senior Vice President, Translational Medicine

Gary has over 15 years of drug discovery and translational research experience at both strategic and operational levels. Before joining QED, he was VP, Head of Oncology Research at Ignyta, a precision oncology company recently acquired by Roche. Prior to Ignyta, Gary held various leadership positions at Pfizer and Johnson & Johnson. During his career, he has made important contributions to multiple oncology treatments, including axitinib, crizotinib, dacomitinib, palbociclib, lorlatinib, and entrectinib. Gary earned his PhD in Biomedical Sciences from the University of Pennsylvania School of Medicine. He holds multiple patents, has published nearly 50 peer-reviewed articles, and has delivered over 70 lectures and meeting presentations.

Board of Directors

Neil Kumar, PhD

President and Chairman of the Board

Neil is the Chief Executive Officer and Founder of BridgeBio Pharma LLC, a company focused on the development of novel therapies for genetic diseases. Prior to founding BridgeBio, he held prominent roles with both established and emerging companies, including Principal at Third Rock Ventures, VP of Business Development and Operations for MyoKardia, and Associate Principal at McKinsey & Company. Additionally, Neil was involved in the formation of a gene chip startup and was a technical consultant for AstraZeneca’s pathway signaling group. Neil is the author of several peer-reviewed papers in the fields of oncology and systems biology. He holds BS and MS degrees in Chemical Engineering from Stanford University, and received his PhD in Chemical Engineering from the Massachusetts Institute of Technology.

Frank McCormick, PhD

Board of Directors

A professor at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Frank has held leadership positions with several San Francisco Bay Area biotechnology firms specializing in cancer care, including Cetus Corp and Chiron Corp. In 1992, he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx, he initiated and led drug discovery efforts that led to the approval of Sorafenib for treatment of renal cell cancer and hepatocellular cancer in the United States as well as approval of ONYX-015 in China for treatment of nasopharyngeal cancer. Frank is the author of over 285 scientific publications and holds 20 issued patents. He served as President (2012-2013) for the American Association for Cancer Research. More recently, he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI-supported national effort to develop therapies against RAS-driven cancers.


Our parent company

BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. Founded in 2015, BridgeBio’s mission is to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 15 development programs includes product candidates ranging from early discovery to late-stage development.

BridgeBio Logo
  • Sign Up

    Stay up to date.

    Receive updates on the development of infigratinib and breaking news from QED Therapeutics.

    *Required fields.

  • Communication Agreement

    By completing this form and clicking the SUBMIT button, you understand and hereby consent to your personal information being stored on a database in the United States and accessible to QED Therapeutics for purposes such as marketing programs from QED Therapeutics, disseminating information about research from QED Therapeutics regarding infigratinib and related health conditions, and obtaining feedback about our products and services. You may request access to, removal, or correction of your personal information by sending an email to: info@QEDTx.com. Please review the full QED Therapeutics privacy policy for more information on your rights with respect to your personal information. If you are a resident of the European Union, please note that by submitting your information to QED through this form, you are expressly consenting to transfer of your personal data to the United States.

  • This field is for validation purposes and should be left unchanged.

Contact Us

75 Federal Street
San Francisco, CA 94107